Use of Chimeric Antigen Receptor-Modified T Cells to Treat Cancer
Summary
The European Patent Office granted Patent EP3660029A1 to The Trustees of the University of Pennsylvania covering chimeric antigen receptor (CAR)-modified T cells for cancer treatment. The patent names inventors Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, and Michael C. Milone. The patent covers methods for treating cancer using CAR-modified T cells, with designations extending across 35 European states.
What changed
The EPO has granted EP3660029A1, a patent covering the use of chimeric antigen receptor (CAR)-modified T cells for treating cancer, specifically including methods for hematological malignancies such as leukemia and lymphoma. The patent designates 35 European Contracting States including Germany, France, UK, Italy, Spain, and other EU member states.
For companies developing CAR-T cell therapies or related immunotherapy products in Europe, this patent establishes intellectual property protection for University of Pennsylvania's CAR-T technology. Competitors may need to assess Freedom to Operate considerations or pursue licensing negotiations. Research institutions and biotech firms working on similar CAR-modified T cell approaches should evaluate potential overlap with the patent's claimed subject matter.
What to do next
- Monitor for updates
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT CANCER
Publication EP3660029A1 Kind: A1 Apr 08, 2026
Applicants
The Trustees of the University of Pennsylvania
Inventors
JUNE, Carl H., LEVINE, Bruce L., PORTER, David L., KALOS, Michael D., MILONE, Michael C.
IPC Classifications
A61K 40/11 20250101AFI20250711BHEP A61K 40/31 20250101ALI20250711BHEP A61K 40/42 20250101ALI20250711BHEP A61K 39/395 20060101ALI20250711BHEP A61K 38/17 20060101ALI20250711BHEP C12N 5/0783 20100101ALI20250711BHEP C07K 16/28 20060101ALI20250711BHEP A61P 35/00 20060101ALI20250711BHEP A61P 35/02 20060101ALI20250711BHEP A61P 37/02 20060101ALI20250711BHEP A61P 37/04 20060101ALI20250711BHEP A61P 43/00 20060101ALI20250711BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.